+

WO2008091679A2 - Procédé et kit pour la détection de fusion de gènes mbcr/abl et de c-kit (cd117) - Google Patents

Procédé et kit pour la détection de fusion de gènes mbcr/abl et de c-kit (cd117) Download PDF

Info

Publication number
WO2008091679A2
WO2008091679A2 PCT/US2008/000958 US2008000958W WO2008091679A2 WO 2008091679 A2 WO2008091679 A2 WO 2008091679A2 US 2008000958 W US2008000958 W US 2008000958W WO 2008091679 A2 WO2008091679 A2 WO 2008091679A2
Authority
WO
WIPO (PCT)
Prior art keywords
kit
probe
gene
bcr
tagged
Prior art date
Application number
PCT/US2008/000958
Other languages
English (en)
Other versions
WO2008091679A3 (fr
Inventor
Patrick J. Muraca
Original Assignee
Nuclea Biomarkers, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nuclea Biomarkers, Llc filed Critical Nuclea Biomarkers, Llc
Priority to EP08713271A priority Critical patent/EP2126118A4/fr
Publication of WO2008091679A2 publication Critical patent/WO2008091679A2/fr
Publication of WO2008091679A3 publication Critical patent/WO2008091679A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Definitions

  • Chronic myeloid (or myelogenous) leukemia is characterized by new and genetically different marrow stem cells that produce increased numbers of myeloid cells (the white blood cells that normally engulf foreign matter and fight infection).
  • the increase in CML tumor stem cells appears to suppress the normal blood cell precursors.
  • Gale, R.P. 1991, "Chronic myelogenous leukemia: Molecule to man,” Henry Ford Hospital MedicalJournal, 39:2:108-111.
  • the disease involves a pluripotent stem cell, it is the myeloid lineage that usually predominates.
  • CML is dependent on a genetic alteration that results in a fusion between the ABLl gene on chromosome 9 and the BCR gene on chromosome 22.
  • the genetic alteration is called the Philadelphia chromosome (Ph or Ph 1 ) for the city where it was first described. Nowell, PC and Hungerford, DA, 1960, "A minute chromosome in human chronic granulocytic leukemia," Science, 132:1497.
  • the corresponding molecular alteration consists of a reciprocal translocation so that most or all of the oncogene ABLl moves from 9q34 to the BCR gene on chromosome 22 into a region known as the breakpoint cluster region (her).
  • the breakpoint cluster region here.
  • the break mABLl is variable, although highly restricted within the gene, invariably 5' to the second exon, whereas the her breakpoint in CML may vary over the entire gene.
  • Ph chromosome Although the Ph chromosome is found in more than 90 % of CML cases, related alterations mark some of the remaining cases of the disease. Variant or complex rearrangements that include other chromosomal sites as well as breaks at 9q34 and 22qll.2 are observed in approximately 4 to 8% of cases.
  • Fitzgerald, 1991 "Complex Ph Translocations in Chronic Myeloid Leukemia," Cancer Genet Cytogenet, 55: 129- 131 ; De Braekeleer, 1986, "Variant Ph translocations in CML: Is there an uneven geographic distribution?" Cancer Genet Cytogenet, 20:185-186.
  • Ph-negative cases comprise less than 5 % of all CML, since more rigorous criteria for discrimination from other myeloid dysplasias have been established, van der Plas et al, 1991 , "Review of clinical, cytogenetic, and molecular aspects of Ph-negative CML," Cancer Genet Cytogenet, 52:143-156.
  • the gene rearrangement can be detected with probe studies in situ or by Southern blot or PCR, but not by conventional cytogenetics.
  • the Ph chromosome also is observed in other diseases, in a small proportion (3-10%) of children with Acute Lymphocytic Leukemia (ALL), and in approximately 20 to 25 % of adult ALL cases where it is strongly associated with poor survival. It is even less frequent ( ⁇ 2%) in Acute Myeloid Leukemia (AML) and these cases may represent examples of CML where the chronic phase was undetected or very brief Among the ALL cases where the Ph chromosome is present, the same molecular rearrangement found in CML has been reported in about 50% of children and near 50% of adults.
  • ALL Acute Lymphocytic Leukemia
  • AML Acute Myeloid Leukemia
  • CML, ALL and AML also may be characterized by markers in addition to Ph, including c-kit (CDl 17).
  • c-kit CDl 17
  • Kindler et al ' ⁇ fficacy and safety of imatinib in adult patients with c-kit positive acute myeloid leukemia", 2004, Blood, 104(10): 3644-54; Malagola et al. , "Imatinib mesylate in the treatment of c-kit positive acute myeloid leukemia: is this the real target?' 2005, Blood, 105(2): 904-5.
  • Cluster of differentiation (CD) molecules are markers on the cell surface, as recognized by specific sets of antibodies, used to identify the cell type, stage of differentiation and activity of a cell.
  • C-kit is the membrane receptor for stem cell factor (SCF), also known as “steel factor” or "c- kit ligand.”
  • SCF stem cell factor
  • Steel factor is a polypeptide that activates bone marrow precursors of a number of blood cells, but its receptor is also present on other cells.
  • C-kit (CD-I 17) mutations in the interstitial cells of Cajal in the digestive tract are believed to be the key to gastrointestinal stromal tumors (GISTs).
  • the invention comprises methods, compositions and kits for the rapid and accurate identification of the major bcr/abl ⁇ Mbcr/abl) gene fusion and c-kit (CDl 17) amplification status in patients having or suspected of having a lymphoproliferative disorder characterized by the presence of the Mbcr/abl gene fusion and c-kit (CD 117) expression.
  • the present method comprises simultaneously detecting both the presence of Mbcr/abl gene fusion and c-kit (CD 117) amplification in a single biological sample of patients having or suspected of having CML or another lymphoproliferative disorder using nucleic acid probes that hybridize to the BCR gene and the ABLl gene, together with a probe or antibody specific for c-kit (CD 117) expression.
  • the present method generally comprises the following steps: (a) disposing a biological sample obtained from a patient on a substrate using standard cytogenetic procedures; (b) if necessary, converting the DNA in the sample from double-stranded to single-stranded by denaturation; (c) contacting the sample with nucleic acid probes complementary to BCR and ABLl gene sequences, and optionally with nucleic acid probes complementary to a c-kit gene sequence, wherein the probes are labeled directly or indirectly with a detectable label; (d) incubating under conditions favorable to the hybridization of the probe DNA sequences and the genomic DNA sequences; and (e) determining the presence and relative positions of the detectable labels.
  • the method of the present invention comprises the following steps: (a) fixing a biological sample, preferably comprising whole cells such as peripheral blood cells or bone marrow, of a patient having or suspected of having CML or other lymphoproliferative disorder to a substrate, preferably a microscope slide; (b) converting the DNA in the sample from double-stranded to single-stranded by denaturation; (c) contacting the sample with DNA probes complementary to BCR and ABLl gene sequences, wherein the probes complementary to the BCR gene are tagged with one member of a first binding pair, and the probes complementary to the ABLl gene are tagged with one member of a second binding pair, and wherein the first and second binding pairs are different; (d) contacting the sample with DNA probes complementary to the c-kit (CDl 17) sequence, wherein the probes are either directly labeled or may be indirectly labeled, e.g., being tagged with one member of a third binding pair, wherein the third binding pair may
  • the kit of the invention comprises (a) DNA probes comprising a DNA sequence complementary to the BCR gene tagged with a first detectable label or with one member of a first binding pair, a DNA sequence complementary to the ABLl gene tagged with a second different detectable label or with one member of a second different binding pair; and a DNA probe comprising a DNA sequence complimentary to the c-kit gene tagged directly with a detectable label or with a member of a third binding pair, (b) detection reagents for detection of hybridized probes; and (c) optionally, a counterstain for staining non-hybridized DNA.
  • the kit optionally may contain reagents for denaturation and/or washing.
  • the present method and kit may include an antibody specific for c-kit (CD 117) rather than a DNA probe.
  • an antibody directed against the c-terminal domains of the c-kit (CD 117) protein is used, which recognizes both wild type and mutant forms of the c-kit (CD 117) protein.
  • the Mbcr DNA probes comprise overlapping cosmid clones which hybridize to the centromeric (5 1 ) side of the major breakpoint cluster region Mbcr within the BCR gene, and the abl DNA probes comprise four overlapping cosmid clones which hybridize to the telomeric (3') side of the ABLl gene.
  • the c-kit probes preferably constitute a sequence that hybridizes to at least a portion of the c-kit (CD-I 17) gene.
  • the present method and kit utilize in situ hybridization (ISH), preferably fluorescence in situ hybridization (FISH), to detect the presence of the Ph chromosome and c-kit (CD 117) expression
  • ISH in situ hybridization
  • FISH fluorescence in situ hybridization
  • the present invention can be used for the diagnosis and/or monitoring of disease progression for lymphoproliferative disorders characterized by the presence of the Ph chromosome and c-kit (CD 117), including CML, AML and ALL, and for predicting the efficacy of certain therapeutic agents for treating such disorders.
  • the present method and kit can be used to predict the efficacy of therapeutic agents which are inhibitors of a tyrosine kinase enzyme, the BCR/ABL fusion protein and c-kit (CDl 17), such as imatinib mesylate (Gleevec®), dasatinib (SprycelTM) or nilotinib (TasignaTM).
  • Figure 1 A shows the location ofhybridizatbn of the probes used in the present method to the BCR gene on chromosome 22 and the ABLl gene on chromosome 9;
  • Figure 1 B shows the location ofhybridization of the probes used in the present method to the fused mbcr/abl site on chromosome 22.
  • Figures 2A-B show the specific location of the BCR and ABL genes on both 22ql 1.2
  • FIG. 2C shows the relationship of probes of the present invention in normal patient interphase nuclei.
  • Figure 2D shows the relationship of probes of the present invention in a "fusion" configuration in tumor interphase nuclei.
  • Figure 3 A shows the relationship of the c-kit gene probe on 4q 12 in relation to the centromere.
  • Figure 3B shows the relationship of the probes of the present invention in tumor interphase nuclei
  • CML lymphoproliferative disorders
  • C-kit is a tyrosine kinase receptor which is expressed in a wide variety of tumor cells.
  • Therapeutic agents that inhibit c-kit (CD 117) as well as the bcr-able fusion protein are effective for treating these disorders.
  • Such therapeutic agents include imatinib mesylate (Gleevec®), dasatinib (SprycelTM) and nilotinib. These agents may be more effective in those patients who are both Ph positive and c-kit positive.
  • the present test can identify patients that are Ph + and c-kit negative, and Ph " and c-kit positive, who also may benefit from therapy with these agents.
  • the present invention comprises methods, compositions and kits for the rapid and accurate identification and co-localization of the major bcr/abl (Mbcr/abl) gene fusion and c-kit (CDl 17) amplification status in a single biological sample obtained from patients having or suspected of having a lymphoproliferative disorder, including CML, AML or ALL.
  • Mbcr/abl major bcr/abl
  • CDl 17 c-kit
  • the present method comprises simultaneously detecting the presence of and co- localizing Mbcr/abl gene fusion and c-kit (CD 117) amplification in a single biological sample of a patients having or suspected of having CML or another proliferative disorder using nucleic acid probes that hybridize to the BCR gene and the ABLl gene, together with a probe or antibody specific for c-kit (CDl 17) expressioa
  • the biological sample may be whole cells and preferably is cultured or uncultured bone marrow or peripheral blood cells.
  • the present method generally comprises the following steps: (a) disposing a biological sample obtained from a patient on a substrate using standard cytogenetic procedures; (b) if necessary, converting the DNA in the sample from double-stranded to single- stranded by denaturation; (c) contacting the sample with nucleic acid probes complementary to BCR end ABLl gene sequences and with a nucleic acid probe complementary to a c-kit gene sequence, wherein the probes are labeled with a detectable label; (d) incubating under conditions favorable to the hybridization of the probe DNA sequences and the genomic DNA sequences; and (e) determining the relative positions of the detectable labels.
  • label refers to any atom or moiety which can be used to provide a detectable (preferably, quantifiable) signal, and which can be attached to a polynucleotide, primer or probe.
  • label and conjugation techniques including direct and indirect labeling, are known and are reported extensively in both the scientific and patent literature. Examples of labels that can be used include radionucleotides, enzymes, substrates, cofactors, inhibitors, fluorescent moieties, chemiluminescent moieties, magnetic particles, and the like.
  • the nucleic acid probes used in the present invention may be either directly labeled, e.g., using quantum dots or fluorescent compounds linked directly to the probe; or indirectly labeled, e.g., wherein a first member of a binding pair (such as streptavidin-biotin) is linked to the probe, and the label is attached to the second member of the binding pair.
  • Preferred detectable labels for use in the present invention include quantum dots and fluorescent compounds.
  • Direct and indirect labeling techniques and fluorophores useful as detectable labels are taught, for example, in U.S. Patent No. 7,316,931.
  • the use of quantum dots for labeling biological compounds is taught, for example, in U.S. 7,235,361.
  • the method of the present invention comprises the following steps: (a) fixing a biological sample preferably comprising peripheral blood cells or bone marrow of a patient having or suspected of having CML to a substrate, preferably a microscope slide; (b) converting the DNA in the sample from double-stranded to single- stranded by denaturation; (c) contacting the sample with a DNA probe complementary to BCR and ABLl gene sequences, wherein the probe complementary to the BCR gene is tagged with one member of a first binding pair, and the probe complementary to the ABLl gene is tagged with one member of a second binding pair, and wherein the first and second binding pairs are different; (d) contacting the sample with a DNA probe complementary to a c-kit gene sequence, wherein the probe is either directly labeled or labeled with one member of a third binding pair; (e) incubating under conditions favorable to the annealing of the probe DNA sequences and the genomic DNA sequences in the patient sample; (f) optionally washing
  • ISH in situ hybridization
  • the present method and kit comprise the use of cosmid probe sets, one set containing a portion of the 5' end of the BCR gene; the other set containing sequences from the extreme 3' end of the ABLl gene, each linked with a different fluorophor, so that fusion or close approximation of two differently colored signals can be visualized.
  • a separate probe is constructed for detecting c-kit (CD 117); that probe may be any sequence capable of hybridizing with all or a portion of the c-kit gene.
  • the c-kit probe may be labeled directly, e.g. using quantum dot technology, or indirectly, e.g., using a fluorophore attached to one member of a binding pair.
  • the present method is rapid, sensitive, and semiquantitative. It permits detection of the Mbcr/abl rearrangement and c-kit expression when a dividing cell population is unavailable, and has the added advantage of localizing the alteration to the tumor cell lineage.
  • FISH Fluorescence Activated FISH
  • a new cytogenetic variant detected by FISH in two Ph-negative, BCR-positive patients with chronic myeloid leukemia Genes, Chromosomes & Cancer, 8:237-245.
  • FISH also has been used for determining c-kit mutations.
  • Debiec-Rychter, et al, 2001 "Chromosomal aberrations in malignant gastrointestinal stromal tumors: correlation with c-KIT gene mutation," Cancer Genet Cytogenet; 128(1): 24-30 and Beghini, A., et al, 2000, 'Trisomy leading to duplication of a mutated KIT allele in acute myeloid leukemia with mast cell involvement," Cancer Genet Cytogenet; 119(1):26-31.
  • the simultaneous detection and/or co-localization of the Mbcr/abl gene fusion and c-kit (CD 117) expression in a single patient sample is new.
  • the kit of the invention comprises (a) DNA probes comprising at least one probe comprising a DNA sequence complementary to the BCR gene tagged with a first detectable label or with one member of a first binding pair, at least one probe comprising a DNA sequence complementary to the ABLl gene tagged with a second different detectable label with one member of a second different binding pair, and at least one probe comprising a DNA sequence complementary to the c-kit (CD 117) gene either directly labeled or tagged with one member of a third binding pair, (b) detection reagents for detection of hybridized probes; and (c) optionally, a counterstain for staining non-hybridized DNA
  • the kit optionally may contain reagents for denaturation and/or washing
  • the Mbcr DNA probe comprises overlapping cosmid clones which hybridize to the centromeric (5*) side of the major breakpoint cluster region (Mbcr) within the BCR gene; and the abl DNA probe comprises four overlapping cosmid clones which hybridize to the telomeric (3') side of the ABLl gene.
  • the c-kit DNA probe preferably comprises a sequence which hybridizes to all or a portion of the c-kit gene (4ql2).
  • DNA probes useful in the present method and kit are those that hybridize to areas of the BCR and ABLI gene located on either side of the major breakpoint cluster regions: The following probe/primer sequences are preferred for use in the present invention:
  • Probe Set 1 A BAC clone proximal to the MTC region of the BCLl locus on 1 IqI 3 is generated by using the following primers 5 'AAGGTGTGAGGATCACTGGS' (SEQ ID NO. 1), 5 ⁇ GCTCATGGGGGCTATT3' (SEQ ID NO. 2) derived from the Dl 1S1337 by screening a BAC library. In the nuclei carrying the translocation, this probe remains on the der(l 1) chromosome and generates a fusion or co-localizing signal in combination with the IGH probe from region 3.
  • Probe Set 2 A BAC clone telomeric to the BCLl gene region (is generated by using the following primers 5 1 TTTCTGGGTGTGTCTGAATS' (SEQ ID NO. 3), 5'ACACAGTTGCTCT AAAGGGT3' (SEQ ID NO. 4) derived from the FGF3 gene.
  • this probe segregates to the der(l 4) chromosome in translocations involving all the MTC, mTCl and mTc2 breakpoints within the BCLl locus on 1 IqI 3, and results in a fusion or co-localizing signal with the IGH probe from region 4.
  • Probe Set 3 A BAC clone covering the probe 3 region of the IGH gene is generated using the following primers derived from the sub-telomeric V region of the IGH gene to screen the BAC library: 5 TGTTTG AAG AAGGG AGTCGT3' (SEQ ID NO. 5); 5'CCCACTCCATGTCTTCTGTTS' (SEQ ID NO. 6). In the nuclei carrying the translocation, this probe segregates to the der(l 1) chromosome and generate a fusion or co- localizing signal in combination with probe 1.
  • Probe Set 4 A BAC clone covering the probe 4 region of the IGH gene is generated using the following primers derived from the C region to screen the library: 5'CCACTCAGTGTGACCTGGAGCGAAS' (SEQ ID NO. 7); 5'CTCCCCTGGCTTTTCTGGAACTGG3' (SEQ ID NO. 8). In the nuclei carrying the translocation, this probe remains on the der(14) chromosome and generates a fusion or co- localizing signal in combination with the relevant BCLl probe.
  • Probe Set 5 A BAC clone centromeric to all the three classes of breakpoints in the MYC region are generated using the following primers 5'GGCAAATTGGTTTAAGTGGAS' (SEQ ID NO. 9); 5'ACAGGGGAATGGTTAACTGG 3' (SEQ ID NO. 10) derived from WI- 1120. In nuclei carrying the translocation, this probe remains on the der(8) chromosome and generates a fusion or co-localizing signal in combination with the IGH probe from region 3
  • Probe Set 6 A BAC clone telomeric to all the breakpoints in the MYC gene is generated from the exon 2 region of MYC gene using the following primers 5 • ATGCCCCTCAACGTTAGCTTC3 • (SEQ ID NO. 11); 5 1 CAGAGTCGCTGCTGGTGGTS' (SEQ ID NO. 12). In the nuclei carrying the translocation, this probe segregates to the der(14) chromosome in all three class types of breakpoints (i.e., breakpoints involving the first intron, the first exon, or further centromeric region breakpoints) and results in a fusion or co-localizing signal with IGH probe from region 4.
  • breakpoints i.e., breakpoints involving the first intron, the first exon, or further centromeric region breakpoints
  • Probe Set 7 A BAC clone covering the probe 3 region of the IGH gene is generated using the following primers derived from the sub-telomeric V region of the IGH gene to screen the BAC library: 5TGTTTGAAGAAGGGAGTCGT3 1 (SEQ ID NO. 13); 5'CCCACTCCATGTCTTCTGrTS 1 (SEQ ID NO. 14). In the nuclei carrying the translocation, this probe segregates to the der(l 1) chromosome and generates a fusion or co- localizing signal in combination with probe 2.
  • Probe Set 8 A BAC clone covering the probe 4 region of the IGH gene is generated using the following primers derived from the C region to screen the library: 5 1 CCACTCAGTGTGACCTGGAGCGAAS' (SEQ ID NO. 15); 5 1 CTCCCCTGGCrTTTCTGGAACTGGS 1 (SEQ ID NO. 16). In the nuclei carrying the translocation, this probe remains on the der(14) chromosome and generates a fusion or co- localizing signal in combination with the probe 2.
  • Probe Set 9 A BAC clone covering the probe 1 region of the BCL2 gene was generated using the following primers from the region centromeric to BCL2 gene to screen the library: 5'CTTGCCTCCTAAGCCAGTTG3' (SEQ ID NO. 17);
  • Probe Set 10 A BAC clone covering the probe 2 region of the BCL2 gene was generated using primers from the region telomeric to BCL2 gene: 5TGGCCAGCAGCAGTGTCAAATAG3' (SEQ ID NO. 19),
  • Probe Set 11 A BAC clone covering the probe 3 region of the IGH gene was generated using the following primers derived from the sub-telomeric region of chromosome 14q. 5TGTTTGAAGAAGGGAGTCGT3' (SEQ ID NO. 21); 5'CCCA CTCCATGTC TTCTGTT3' (SEQ ID NO. 22). In the nuclei carrying this translocation, the probe segregates to the der(l 8) chromosome and generates a fusion or co-localizing signal in combination with probe 1 in t(14;18)(q32;q21) cases.
  • Probe Set 12 A BAC clone covering the probe 4 region of the IGH gene was generated using the following primers derived from the C region: 5'CCCTGGACGCTTTTCAAATAS' (SEQ ID NO. 23); 5'GACTCAGGCAAGGACAAAGC3 I (SEQ ID NO. 24). In the nuclei carrying the translocation, this probe will remain on the der(14) chromosome and generate a fusion or co- localizing signal in combination with probe 2 from 18q21 region in t(14;18)(q32;q21) cases.
  • Probe Set 13 The juxtamembrane domain of the c-kit (FLT3) receptor cDNAs were amplified by RT-PCR, and one of the primers was FAM labeled. Primer sequences were 5'GCAATTTAGGTATGAAAGCCAGC3 I (SEQ ID NO. 25) and
  • any two MBCR probe sets may be combined with any two ABLl probe sets (probe sets 7-10) or anytwo MBCR or ABLl probe sets (probe sets 11-12).
  • the fifthprobe set is the C-kit probe set (probe set 13).
  • the present method and kit utilize in situ hybridization (ISH), preferably fluorescence in situ hybridization (FISH), to detect the presence of the Philadelphia chromosome and c-kit (CD 117) expression.
  • c-kit (CD 117) expression can be detected using a labeled polyclonal or monoclonal antibody specific for c-kit (CD 117) protein.
  • ISH in situ hybridization
  • FISH fluorescence in situ hybridization
  • the present method and kit can be used for the diagnosis and/or monitoring of disease progression for lymphoproliferative disorders and for predicting and/or monitoring the efficacy of certain therapeutic agents for treating disorders characterized by the presence of the Ph chromosome and c-kit, including CML, AML and ALL.
  • the present method and kit can be used to predict the efficacy of therapeutic agents which are inhibitors of tyrosine kinase, the BCR/ ABL fusion protein and c-kit (CDl 17), such as imatinib mesylate (Gleevec®), dasatinib (SprycelTM) and/or nilotinib.
  • the method and kit of the present invention utilize a set of DNA probes and detection reagents that yield an easily readable fluorescent signal, preferably a red fluorescent signal at the site of the BCR gene, a green fluorescent signal at the site of the ABLl gene, and a green fluorescent signal at the site of the c-kit gene, on a blue fluorescent background of nuclear or chromosomal DNA.
  • Preferred probes are those having the sequences shown as SEQ ID NOs. 1-26.
  • four probes specific for MBCR selected from probe sets 1-6 (SEQ ID NOs. 1-12) are combined with four probes specific for ABLl or for both ABLl or MBCR selected from probe sets 7- 12 (SE ID Nos. 13-24).
  • probe set 13 SEQ ID NOs. 25-26
  • the method and kit yield these results on both metaphase chromosomes and interphase nuclei of bone marrow and peripheral blood cells.
  • the c-kit label may be any color, however.
  • the method of the present invention comprises the following steps: (a) a biological sample preferably comprising whole cells, preferably peripheral blood cells or bone marrow of a patient having or suspected of having CML is fixed to a substrate, preferably a microscope slide, using standard cytogenetic procedures; (b) the DNA in the sample is converted from double-stranded to single-stranded by denaturation at about 70 °C using a mixture of the 2OX SSC and Formamide Reagents supplied in the kit; (c) the labeled DNA probes complementary to BCR, ABLl and c-kit gene sequences are applied to the slide, which then is incubated under conditions favorable to the annealing of the probe DNA sequences and the genomic DNA sequences; (d) unannealed probe is washed off using a mixture of the 2OX SSC and Formamide Reagents, and the hybridized probes are detected by an indirect methodology using fluorescently-tagged ligands which bind to the labels on the DNA probes is and
  • a kit according to the invention comprises (a) labeled DNA probes comprising DNA sequences complementary to the BCR gene on chromosome 22, the ABLl gene on chromosome 9 and the c-kit (CD 117) gene on chromosome 4 (location 4q 12); (b) detection reagents for fluorescent detection of hybridized probes; and (c) fluorescent counterstain.
  • the kit optionally also may contain reagents for denaturation and/or washing.
  • iheMbcr DNA probes comprise the sequences shown herein as SEQ ID NOs. 1-12
  • the abl DNA probes comprise the sequences shown herein as SEQ ID NOs. 13-24
  • the c-kit DNA probes comprise the sequences shown herein as SEQ ID NOs. 25 and 26.
  • the detection reagent permits simultaneous detection of hybridized Mbcr, abl and c-kit (CD 1 17) DNA sequences.
  • the detection reagent comprises rhodamine-conjugated anti-digoxigenin antibody and fluorescein isotinocyanate- conjugated avidin.
  • the digoxigenin-labeled Mbcr probe is detected by the anti-digoxigenin antibody, the anti-digoxigenin antibody binds with high affinity to the digoxigenin label on the probe, thereby immobilizing the fluorescent rhodamine at the site of the BCR gene.
  • the biotin-labeled abl probe is detected by the avidin; the avidin binds with high affinity to the biotin label on the probe, thereby immobilizing the fluorescein at the site of the ABLl gene. Subsequent washing with phosphate buffered detergent (PBD) reagent in the kit removes unbound detection reagent.
  • PBD phosphate buffered detergent
  • the c-kit probe can be labeled directly (e.g. using Q-dots), or indirectly (e.g., using the rhodamine-conjugated anti-digoxigenin antibody/digoxigenin binding pair or the fluorescein isotinocyanate-conjugated avidin/biotin binding pair).
  • the counterstain reagent utilized in a preferred embodiment of the present kit comprises DAPI (4',6'-diamidino-2-phenylindole) and, optionally, an antifade agent.
  • DAPI stains the nuclear or chromosomal DNA uniformly by intercalating between bases in the DNA double helix.
  • the antifade component retards photobleaching of the fluorescent signal.
  • Excitement of rhodamine, fluorescein, and DAPI by light from a mercury arc lamp in a fluorescence microscope results in the emission of red, green and blue light, respectively.
  • the observer selects for these three colors by using the appropriate microscope filter, and simultaneously scores nuclei or metaphase chromosomes for the presence of red, green, or fused red-green signals on a blue background.
  • the method and kit of the present invention provide information about the number of major bcr/abl fusion events that are present in an assayed cell, and can be used in the diagnosis of patients who are suspected of having CML, AML, ALL or clinically similar lymphoproliferative disorders.
  • the present method and kit can detect the appearance of a second Mbcr/abl fusion event, which often is characteristic of disease progression to theblastic phase of CML; therefore, they can be used as a clinical tool to determine whether a patient has entered the blastic phase, or to guide changes in therapy intended to address the blastic phase of the disease.
  • ALL acute lymphocytic leukemia
  • AML acute myebid leukemia
  • the DNA probe in the present method and kit detect the major her breakpoint, which is the site of translocation in CML and in AML or ALL cases that exhibit a Philadelphia chromosome.
  • the Mbcr/abl fusion in such cases can be detected by the present assay.
  • the method and kit of the present invention also can be used to test individuals with clinical indications of lymphoproliferative disease in order to rule out CML.
  • Three sets of slides were prepared, each set containing the test samples and three control samples: five (5) samples of each from normal, CML c-kit positive and CML c-kit negative patients.
  • One set of the three specimens was denatured, hybridized and post- washed at the recommended temperatures, another set was assayed at -1°C from the recommended temperatures, and the third set was assayed at -2°C from the recommended temperatures.
  • the sample were masked and then scored using the scoring criteria provided below.
  • Each of the 9 slides (3 per patient sample) was evaluated for the presence of the Mbcr/abl fusion product in each of 200 interphase nuclei. When present, up to 20 metaphase spreads per slide were also evaluated for the fusion product.
  • Nuclei from the samples were fixed by standard cytogenetic procedures and applied to a microscope slide.
  • the DNA was converted from double-stranded to single-stranded by denaturation at 70 °C using a mixture of the 2OX SSC and Formamide Reagents supplied in the kit.
  • a mixture of labeled DNA probes complementary to the BCR and ABLl gene sequences prepared as described above were applied to the slide.
  • the Mbcr DNA probes comprised three digoxigenin-labeled overlapping cosmid clones which hybridize to the centromeric (5') side of the major breakpoint cluster region (Mbcr) within the BCR gene (Probe Sets 1 and 2; SEQ ID NOs. 1-4).
  • the abl DNA probes comprised four biotin- labeled overlapping cosmid clones which hybridize to the telomeric (3') side of the ABLl gene (Probe Sets 7 and 8; SEQ ID NOs. 13-16).
  • C-kit probes comprising sequences complementary to a portion of the c-kit gene (Probe Set 13; SEQ ID NOs. 25 or 26), were labeled with biotin and applied to the slide.
  • the slides then were incubated under conditions favorable to the annealing of the probe DNA sequences and the genomic DNA sequences. Unannealed probe was washed off using a mixture of 2OX SSC, and Formamide Reagents. Detection reagents comprising fluorescently-tagged ligands which bind to the labels on the DNA probes were then applied to the slides to detect hybridized probes.
  • the detection reagent contained both rhodamine-conjugated anti-digoxigenin antibody and fluoresceinisothiocyanate-conjugated avidin.
  • the anti-digoxigenin antibody binds with high affinity to the digoxigenin label on the probe, thereby immobilizing the fluorescent rhodamine at the site of the BCR gene.
  • the avidin binds with high affinity to the biotin label on the ABL and c-kit probes, thereby immobilizing the fluorescein at the site of the ABLl and c-kit genes. Subsequent washing with the PBD reagent in the kit removed unbound detection reagent.
  • the remainder of the DNA was then stained with a fluorescent counterstain, DAPI (4',6'-diamidino-2-phenylindole) and antifade was applied.
  • the slide then was observed by epifluorescence illumination on a microscope.
  • Excitement of rhodamine, fluorescein, and DAPI by light from a mercury arc lamp in a fluorescence microscope resulted in the emission of red, green and blue light, respectively.
  • the DNA probes and detection reagents utilized yielded a red fluorescent signal at the site of the BCR gene and a green fluorescent signal at the site of the ABLl gene on both metaphase chromosomes and interphase nuclei of bone marrow and peripheral blood cells, on a blue fluorescent background of nuclear or chromosomal DNA.
  • nuclei which are non-overlapping were scored. Nuclei that are touching but not overlapping may be scored if the point of contiguity does not contain signal.
  • Mbcr appears red
  • abl and c-kit CDl 17
  • c-kit (CDl 17) expression is indicated by the presence of two green spots. Accordingly, the presence of both Mbcr/abl fusions and c-kit (CDl 17) expression is indicated by a yellow or white spot and two green spots. If neither is present, the slide will show two red and two green spots with no yellow or white spots.
  • a normal cell in G2 will show two sets of closely paired green dots and two sets of closely paired red dots.
  • a fusion positive cell in G2 will show one set of closely paired green dots, one set of closely paired red dots and one set of closely paired fusion signals.
  • the percentage of apparent Mbcr/abl fusion positive cells expected in normal individuals is a mean of about 4.8% based on scoring 200 nuclei each in 144 Mbcr/abl fusion negative samples. This study indicated that >96% of Mbcr/abl fusion negative specimens will test between 0 and 11% (95% confidence).
  • the mean percentage of Mbcr/abl fusion positive cells found in CML-affected individuals was 84.9% based on scoring 200 nuclei each in 203 CML patient peripheral blood or bone marrow samples. This study also indicated that >92% of the Mbcr/abl fusion positive specimens will test between the cut-off value of >11% and 100% (95% confidence).
  • the analytical sensitivity of the method was determined from the standard deviation (S. D.) of 25 known normal blood specimens tested. This population had a mean of 3.8% fusion positive interphase nuclei with a S. D. of 1.5. Therefore, the analytical sensitivity of the present method and kit was determined to be about 2x1.5%, or 3.0% interphase nuclei showing Mbcr/abl fusions in a total population of at least 200 interphase nuclei scored.
  • Scoring methods which can be used in the present method include those disclosed by Signoretti et al, "Her-2-neu Expression and Progression Toward Androgen Independence in Human Prostate Cancer," J. Natl. Cancer Instil, 92(23): 1918-25 (2000); Gu et al, "Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer," Oncogene, 19: 1288-96 (2000).
  • PSCA State stem cell antigen
  • chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22; Cell, 36:1 :93-99.
  • the first BCR gene intron contains breakpoints in Philadelphia chromosome positive leukemia; Nucleic Acids Research, 16:21:10069-10081.
  • Ph-negative chronic myeloid leukemia Molecular analysis of ABL insertion into M-BCR on chromosome 22; 76:1812-1818.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne des procédés et des kits permettant l'identification de l'expression principale de fusion de gènes bcr/abl et de c-kit (CD117) chez des patients présentant ou étant suspectés de présenter un trouble prolifératif, caractérisés par la présence de l'expression de fusion de gènes Mbcr/abl et de c-kit (CD117). Le procédé détecte simultanément la présence de la fusion de gènes Mbcr/abl et du c-kit (CD117) dans un échantillon biologique au moyen de sondes d'acide nucléique qui s'hybrident aux gènes BCR et ABLl et détectent une positivité au c-kit (CD117). Le procédé et le kit peuvent être utilisés pour prévoir l'efficacité thérapeutique d'agents inhibiteurs de tyrosine kinase, le c-kit de protéine de fusion BCR/ABL (CD117).
PCT/US2008/000958 2007-01-24 2008-01-24 Procédé et kit pour la détection de fusion de gènes mbcr/abl et de c-kit (cd117) WO2008091679A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP08713271A EP2126118A4 (fr) 2007-01-24 2008-01-24 Procede et kit pour la detection de fusion de genes mbcr/abl et de c-kit (cd117)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89716107P 2007-01-24 2007-01-24
US60/897,161 2007-01-24

Publications (2)

Publication Number Publication Date
WO2008091679A2 true WO2008091679A2 (fr) 2008-07-31
WO2008091679A3 WO2008091679A3 (fr) 2008-12-24

Family

ID=39645079

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/000958 WO2008091679A2 (fr) 2007-01-24 2008-01-24 Procédé et kit pour la détection de fusion de gènes mbcr/abl et de c-kit (cd117)

Country Status (2)

Country Link
EP (1) EP2126118A4 (fr)
WO (1) WO2008091679A2 (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030017491A1 (en) * 2000-09-14 2003-01-23 Zuo-Rong Shi Chromogenic in situ hybridization methods, kits, and compositions
WO2002093130A2 (fr) * 2001-05-14 2002-11-21 Cancer Genetics, Inc. Methodes d'analyse de translocations chromosomiques par hybridation in situ en fluorescence

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of EP2126118A4 *

Also Published As

Publication number Publication date
EP2126118A4 (fr) 2010-09-01
EP2126118A2 (fr) 2009-12-02
WO2008091679A3 (fr) 2008-12-24

Similar Documents

Publication Publication Date Title
Weiss et al. Comparative genomic hybridisation
US5856089A (en) Method for the detection of chromosome structural abnormalities by in situ hybridization to fixed tissue
EP0430402B1 (fr) Méthodes et compositions pour la coloration de chromosomes particuliers
US6025126A (en) Methods and compositions for the detection of chromosomal aberrations
JP5579999B2 (ja) ヒト第２０染色体の２０ｑ１３領域における新規アンプリコンおよびその使用
CA2231349C (fr) Amplifications de la region chromosomale 20q13 servant d'indicateurs pour le pronostic du cancer du sein
EP0757723B1 (fr) Alterations genetiques presentant une correlation avec le cancer du poumon
Liehr et al. Current developments in human molecular cytogenetic techniques
US20180291465A1 (en) Materials and methods for assessment of colorectal adenoma
US7115709B1 (en) Methods of staining target chromosomal DNA employing high complexity nucleic acid probes
EP0500290A2 (fr) Coloration de chromosomes particuliers pour détection des réarrangements génétiques
Jiang et al. Rapid detection of IgH/BCL2 rearrangement in follicular lymphoma by interphase fluorescence in situ hybridization with bacterial artificial chromosome probes
Sen et al. Microdissected double-minute DNA detects variable patterns of chromosomal localizations and multiple abundantly expressed transcripts in normal and leukemic cells
CA2021489C (fr) Methodes et composes pour la coloration specifique de chromosomes
WO2008091679A2 (fr) Procédé et kit pour la détection de fusion de gènes mbcr/abl et de c-kit (cd117)
JP2002541826A (ja) 悪性黒色腫由来のメラニン細胞母斑を区別するための染色体コピー数の変化の検出
WO2013007808A1 (fr) Méthode pour prédire l'issue d'un cancer chez un sujet
Darling et al. Non‐isotopic molecular cytogenetics in neuro‐oncology
US6207376B1 (en) Method of detection of polymorphism and loss of heterozygosity in a lung tumor suppressor gene
Bridge et al. Genetics of soft tissue tumors
PIRRoTTA et al. Chromosomal Localizations and Multiple Abundantly Expressed Transcripts in Normal and Leukemic Cells
Haralambieva Detection of chromosomal breakpoints in B-cell neoplasia by interphase fluorescence in situ hybridization on routine paraffin sections
Gray et al. Compositions for chromosome-specific staining
Wurm et al. Cytogenetic Characterization of Recombinant Cells
NZ245427A (en) Methods and compositions for chromosome-specific staining

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08713271

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2008713271

Country of ref document: EP

NENP Non-entry into the national phase in:

Ref country code: DE

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载